Study of GBR 1302 (CD3 Bispecific Ab) in HER2-positive Metastatic Breast Cancer

Condition:   Breast Cancer Interventions:   Biological: GBR 1302 250 ng/kg;   Biological: GBR 1302 325 ng/kg;   Biological: GBR 1302 325 ng/kg-D1;425 ng/kg -D8,D15,D22;   Biological: GBR 1302 325 ng/kg-D1;550 ng/kg -D8,D15,D22;   Biological: GBR1302 325ng/kgD1;550 ng/kg D8;700 ng/kgD15,22;   Biological: GBR1302 325ng/kg D1;55 0 ng/kg D8;900 ng/kg D15,22;   Biological: GBR1302 escalating doses,1200 ng/kg D15,22;   Biological: GBR1302 at the MTD and/or RP2D dose Sponsor:   Glenmark Pharmaceuticals S.A. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials